Tumor lysis syndrome is a potentially life-threatening metabolic emergency that happens when large numbers of cancer cells break apart rapidly, dumping their internal contents into the bloodstream. The sudden flood of potassium, phosphorus, uric acid, and other substances overwhelms the body’s ability to clear them, leading to dangerous electrolyte imbalances, kidney damage, heart rhythm problems, and sometimes death. It occurs most often after the start of cancer treatment but can occasionally happen on its own, before any therapy begins.
What Actually Happens Inside the Body
Every cell contains high concentrations of potassium, phosphorus, and nucleic acids. Cancer cells, particularly those that divide rapidly, tend to pack even more of these substances than normal cells do. When chemotherapy, targeted therapy, or radiation kills a large volume of tumor cells at once, all of that intracellular material spills into the blood faster than the kidneys and liver can process it. The result is a cascade of metabolic problems that can escalate within hours.
The nucleic acids released from dying cells get broken down into purines, which are eventually converted into uric acid. Humans lack the enzyme that most other mammals have to convert uric acid into a more soluble compound called allantoin, so we are especially vulnerable to uric acid buildup. Excess uric acid can crystallize in the kidney tubules, blocking them and reducing the kidneys’ filtering capacity. There may also be crystal-independent mechanisms that contribute to kidney damage in this setting.1American Journal of Kidney Diseases. Tumor Lysis Syndrome: New Challenges, Recent Advances and Clinical Management
At the same time, phosphorus floods out of the lysed cells. Cancer cells carry higher phosphorus concentrations than normal tissue, so the spike can be dramatic. When phosphorus levels rise sharply, calcium in the blood binds to it, forming calcium-phosphate complexes. This drives calcium levels down and can deposit crystals in the kidneys, a process called nephrocalcinosis, which compounds the kidney injury already underway.2PubMed Central. Diagnosis and management of tumor lysis syndrome
The potassium surge is often the most immediately dangerous piece. The heart is exquisitely sensitive to potassium levels; even modest elevations can alter its electrical signaling. When potassium rises sharply, it changes the resting electrical charge of heart muscle cells, which can trigger abnormal rhythms ranging from mild irregularities to fatal cardiac arrest.3BMJ Case Reports. Severe hyperkalaemia in the setting of tumour lysis syndrome A case report documented a patient with diffuse large B-cell lymphoma who died of a fatal arrhythmia caused by the abrupt potassium release at the start of treatment, compounded by a potassium-sparing diuretic the patient was already taking.4PubMed Central. Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B‐cell lymphoma upon start of R‐CHOP
Who Is Most at Risk
The cancers most strongly associated with tumor lysis syndrome are the fast-growing blood cancers: acute leukemias and aggressive lymphomas. These malignancies combine a high cell-division rate with large tumor burdens and strong sensitivity to chemotherapy, a recipe for massive cell death in a short window. Among pediatric cancers, children with B-cell acute lymphoblastic leukemia had the highest risk in a large study, with about a quarter of those patients developing the syndrome. Children with Burkitt’s lymphoma or leukemia who also had elevated lactate dehydrogenase (LDH, a marker of cell turnover) faced roughly a 15% risk.5PubMed. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase
Solid tumors were once thought to carry negligible risk, but that picture has shifted. A systematic review of reported solid-tumor cases found that the most common culprits were liver cancer, lung cancer, melanoma, breast cancer, prostate cancer, and colon cancer. Three-quarters of affected patients had metastatic disease, and about a quarter had bulky tumors or elevated LDH before treatment.6PubMed Central. Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases A separate analysis of U.S. hospital data from 2016 to 2019 found that among solid tumors, uterine cancer patients had the highest odds, followed by lung, breast, pancreatic, and liver cancer.7Journal of Clinical Oncology. Tumor lysis syndrome in solid tumors: A retrospective cohort study of the National Inpatient Sample from 2016 to 2019
The mortality numbers for solid-tumor TLS are sobering. In the systematic review, more than half of the patients who developed it died.8PubMed Central. Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases Part of that high death rate likely reflects the fact that solid-tumor TLS often catches clinicians off guard because it is not expected in these cancers the way it is in leukemia or lymphoma.
Spontaneous Tumor Lysis Syndrome
Most cases are triggered by treatment, but roughly a quarter of solid-tumor cases in one review occurred spontaneously, before any cancer therapy had been given.9PubMed Central. Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases In blood cancers this happens too, typically with very aggressive lymphomas that have high proliferation rates and large tumor masses. A reported case involved a 75-year-old patient with high-grade B-cell lymphoma whose tumor cells were dividing so rapidly that they outgrew their own blood supply, causing massive cell death even without chemotherapy.10PubMed Central. Spontaneous Tumor Lysis Syndrome
Spontaneous TLS is tricky because it can be the very first sign that someone has cancer. A patient arrives at the emergency department with kidney failure, abnormal heart rhythms, or seizures, and the workup reveals both a new malignancy and the metabolic wreckage of lysis. An ICU study found that spontaneous TLS was independently associated with worse one-year survival compared to treatment-induced TLS.11PubMed Central. Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy
How It Is Diagnosed
The standard diagnostic framework, known as the Cairo-Bishop classification, divides the syndrome into laboratory and clinical categories. Laboratory tumor lysis syndrome requires two or more of four metabolic abnormalities (high uric acid, high potassium, high phosphorus, or low calcium) occurring within three days before or up to seven days after the start of treatment. The threshold for each is a 25% change above or below normal, depending on the lab value. Clinical tumor lysis syndrome is diagnosed when those lab findings are accompanied by a real-world consequence: a significant rise in creatinine (indicating kidney injury), a seizure, a cardiac arrhythmia, or death.12PubMed Central. The Tumor Lysis Syndrome13PubMed Central. Prevention and Management of Tumor Lysis Syndrome in Adults With Malignancy
The distinction matters for clinical decision-making. A patient with laboratory TLS alone may need closer monitoring and adjustments to their fluid intake and medications. A patient who has crossed into clinical TLS usually needs intensive care. The challenge is that the lab values can change fast. A patient can look stable one hour and be in cardiac danger the next if potassium spikes suddenly.
Researchers have argued that the current criteria have blind spots. For example, a patient whose kidney function was already impaired before treatment may technically meet TLS criteria without actually having lysis, while a patient with genuine lysis whose baseline labs were already abnormal might not meet the formal thresholds. Investigators are exploring whether biomarkers like LDH, interleukin-6, lactate, or ratios of serum-to-urine uric acid and phosphorus could better distinguish true lysis from other causes of kidney injury.14Kidney and Blood Pressure Research. Pitfalls of Current Diagnostic Criteria of Tumor Lysis Syndrome No single reliable biomarker exists yet, but the push for better tools reflects a real clinical gap.
Newer Cancer Therapies and TLS Risk
The rise of targeted therapies and immunotherapies has not eliminated TLS risk. In some cases it has concentrated it. Venetoclax, a drug widely used for chronic lymphocytic leukemia and certain other blood cancers, has emerged as the single drug most frequently linked to TLS reports in the FDA’s adverse event database.15PubMed. Anticancer Drugs Associated With Tumor Lysis Syndrome: Insights From the US Food and Drug Administration Adverse Event Reporting System Venetoclax is so effective at killing cancer cells that its prescribing protocol now includes a mandatory ramp-up dosing schedule with built-in TLS monitoring at each step.
A systematic review of newer agents found TLS incidence rates of roughly 8 to 9 percent in venetoclax trials and about 10 percent in trials of CAR T-cell therapy and obinutuzumab.16PubMed. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review These numbers may not sound enormous, but they represent real danger in a patient population that is already medically fragile. The point is that TLS is not a relic of old-fashioned chemotherapy; it follows wherever effective cancer cell killing goes.
Prevention Strategies
Prevention centers on two pillars: aggressive hydration and uric acid management. The logic of hydration is straightforward: the more fluid flowing through the kidneys, the better they can flush out the metabolic debris from cell death. Guidelines recommend intravenous fluids starting at least 24 hours before cancer treatment, aiming for a urine output above 100 milliliters per hour in adults, and continuing for one to two days after therapy is complete.17Kidney and Blood Pressure Research. Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress Consensus recommendations call for at least 2 liters per square meter of body surface area per day.18Haematologica. Consensus conference on the management of tumor lysis syndrome
There was a time when doctors routinely added sodium bicarbonate to the IV fluids to make the urine more alkaline, which helps keep uric acid dissolved. That practice has largely fallen out of favor. While alkaline urine does dissolve uric acid better, it creates a new problem: it promotes calcium-phosphate crystal formation, which can cause its own kidney damage. Now that rasburicase (discussed below) is available to handle uric acid directly, most current guidelines no longer recommend routine urine alkalinization.19Kidney and Blood Pressure Research. Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
The first-line drug for uric acid prevention is allopurinol, which blocks the enzyme xanthine oxidase from converting purines into uric acid. It is effective but has a limitation: it prevents the formation of new uric acid but does not break down uric acid that is already circulating. Its dose also needs to be reduced in patients with impaired kidney function or those taking certain other drugs like azathioprine or mercaptopurine, because of dangerous interactions.20PubMed Central. Diagnosis and management of tumor lysis syndrome Febuxostat, a newer xanthine oxidase inhibitor, has been studied as an alternative. A meta-analysis found that febuxostat and allopurinol performed similarly in terms of TLS incidence and uric acid reduction.21Wiley Online Library. Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis
For patients at highest risk, rasburicase is the heavy hitter. It is a recombinant version of the enzyme urate oxidase, the very enzyme humans lack. It converts uric acid directly into allantoin, which dissolves easily and gets cleared by the kidneys without trouble.22PubMed Central. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout Unlike allopurinol, rasburicase can break down uric acid that has already accumulated, making it invaluable in acute situations. The downsides are cost (it is significantly more expensive than allopurinol) and the fact that it cannot be given to patients with a specific enzyme deficiency called G6PD deficiency, because it can trigger severe hemolytic anemia in those individuals.
When Prevention Fails and Treatment Escalates
If the metabolic storm cannot be controlled with fluids and medications, dialysis becomes necessary. Renal replacement therapy can rapidly clear potassium, phosphorus, and uric acid from the blood when the kidneys are overwhelmed.23PubMed. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome Continuous forms of dialysis are generally preferred in critically ill patients because they are gentler on the cardiovascular system than intermittent hemodialysis, and they provide a sustained clearance of the metabolites that keep pouring in as more tumor cells die.
In practice, the decision to start dialysis often depends on how fast the electrolytes are changing as much as their absolute values. A potassium level that is high but stable may be managed with medications and fluids. A potassium level that is rising rapidly despite aggressive measures is a different situation entirely and typically prompts immediate dialysis.
TLS in Children
Children face higher rates of tumor lysis syndrome than adults, largely because the cancers most prone to it, like Burkitt lymphoma and acute lymphoblastic leukemia, are more common in pediatric populations. Fluid management in children follows the same principles but with pediatric-specific targets: hydration of 2.5 to 3 liters per square meter per day, with a target urine output of at least 4 milliliters per kilogram per hour for infants and 100 milliliters per square meter per hour for older children.24PubMed Central. Tumor lysis syndrome in childhood malignancies
The aggressive hydration that prevents TLS creates its own hazard in smaller bodies: fluid overload. A study of 56 pediatric TLS patients found that severe fluid overload occurred in about a third of them, and those children were significantly more likely to need intensive care, develop pulmonary edema, or require low oxygen levels to be treated. Acute kidney injury affected a similar proportion and dramatically increased the need for dialysis and ICU admission.25PubMed. Fluid overload and acute kidney injury in children with tumor lysis syndrome This balancing act between giving enough fluid to protect the kidneys and not giving so much that the lungs fill with fluid is one of the central challenges of pediatric TLS management. Loop diuretics can help, but they need careful timing relative to hydration status.
What Determines Survival
Tumor lysis syndrome itself does not have to be fatal if it is caught early and managed aggressively. But when it leads to acute kidney injury or cardiac arrest, outcomes worsen fast. An ICU study of patients requiring urgent chemotherapy found that the need for mechanical ventilation and vasopressors (drugs that support blood pressure) were the strongest predictors of death within a year. Older age and delays in starting chemotherapy also increased mortality.26PubMed Central. Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy
A large analysis of hospitalized adults with TLS found that age, existing health conditions (as measured by the Charlson Comorbidity Index), and sex were all significant predictors of dying in the hospital, with female patients showing a slightly higher mortality risk in that dataset.27Journal of Clinical Oncology. Exploring the weekend effect and other predictors of mortality in tumor lysis syndrome among hospitalized adults The takeaway is that TLS is most dangerous when it layers on top of other medical vulnerabilities: older age, kidney disease, heart disease, or a delay in recognition and treatment.
Drug Interactions That Amplify the Danger
One underappreciated risk factor is the medications a patient is already taking when TLS hits. Potassium-sparing diuretics like spironolactone, ACE inhibitors, and angiotensin receptor blockers all tend to raise potassium levels or slow its excretion. In a patient whose potassium is already surging from tumor lysis, these medications can push levels into immediately life-threatening territory. The fatal arrhythmia case mentioned earlier specifically noted that the patient’s concurrent use of spironolactone likely worsened the potassium spike.28PubMed Central. Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B‐cell lymphoma upon start of R‐CHOP
Similarly, allopurinol requires dose adjustments in the setting of kidney injury or when the patient is taking azathioprine or mercaptopurine, immunosuppressive drugs sometimes used in cancer care. Failing to reduce the allopurinol dose can lead to toxic drug accumulation.29PubMed Central. Diagnosis and management of tumor lysis syndrome Nonsteroidal anti-inflammatory drugs (NSAIDs) and certain contrast dyes used in imaging can also impair kidney function and worsen outcomes. In practice, part of preparing a patient for high-risk chemotherapy involves auditing their entire medication list and suspending anything that could worsen the metabolic problems TLS brings.
For solid-tumor patients, who are less often on the clinical radar for TLS, this medication review is less likely to happen preemptively, which may partly explain the higher mortality rates seen in that group. The systematic review of solid-tumor TLS found that the most commonly reported lab abnormality was high uric acid, present in 95% of cases, followed by elevated creatinine in 85% and high phosphorus in 83%, suggesting that kidney injury is nearly universal when solid-tumor TLS occurs.30PubMed Central. Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases By the time the diagnosis is made, the window for prevention has often closed.